Quarta-Rad, Inc.

What they do

The Company historically sold radiation detection devices but has shifted focus to software development via its wholly owned subsidiary, Sellavir, Inc. Sellavir provides customized AI and development services, including image processing and the CenterEye platform for call center operations. Current revenue is primarily from a Japanese reseller relationship.

Revenue drivers

• Sellavir software development services — Generated $235,000 in software development revenue in 2025 through a contract with Star Systems Corporation, a 488% increase from 2024.
• Radiation detection products — Historically the core business, but activities have been significantly reduced; Q1 2026 sales were only $856.
• CenterEye subscription platform — A software platform for call centers, intended to be offered as a subscription; revenue recognition began in 2024 but no client details are disclosed.

Recent performance

For the year ended December 31, 2025, revenue was $244,955 with a net loss of $256,929, compared to revenue of $106,797 and a net loss of $216,755 in 2024. Quarterly revenue declined from $82,269 in Q4 2025 to $25,856 in Q1 2026. In Q1 2026, the Company reported a net loss from operations of $94,931, with Sellavir generating $25,000 in sales. As of March 31, 2026, cash and equivalents were $14,568 and shareholder equity was $38,357.

Strategy

Management is focused on the development and commercialization of CenterEye, targeting the call center market. They plan to integrate with major platforms including Genesys Cloud, NICE CXone, and Avaya. They are actively pursuing opportunities in the US, Japan, and other international markets, and aim to expand the customer base beyond the current Japanese reseller.

Risks

• Going concern uncertainty — The independent auditor has expressed substantial doubt about the Company's ability to continue as a going concern due to accumulated deficit and working capital deficit.
• Limited revenue concentration — Sole revenue stream is from a Japanese reseller; no US clients currently.
• Material weaknesses in internal controls — Management identified material weaknesses in internal control over financial reporting, including inadequate segregation of duties and lack of an independent audit committee.
• Insufficient working capital — The Company does not have sufficient working capital to sustain operations for the next twelve months without additional financing or significant revenue increase.

Outlook

Management expects to increase revenues through Sellavir and has entered an Independent Software Vendor Partner Agreement with Genesys Cloud Services in January 2026 to expand the addressable market for CenterEye. However, they caution that there can be no assurance of generating sufficient revenue or obtaining financing, and may be unable to continue operations if these efforts fail.